Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04218071 · ClinicalTrials.gov registry record · Phase 2
Actuate 1901: 9-ING-41 in Myelofibrosis
A Phase 2 study, sponsored by Actuate Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT04218071 is a Phase 2 study that has completed, run by Actuate Therapeutics. The registered enrollment target is 17 participants.
The verdict
NCT04218071, a Phase 2 study, has completed, sponsored by Actuate Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
9-ING-41 has anti-cancer clinical activity while not causing myelosuppression, and has both pre-clinical anti-fibrotic activity and activity against myelofibrosis. This Phase 2 study will study its efficacy in patients with advanced myelofibrosis.
Interventions
- DRUG Ruxolitinib
- DRUG 9-ING-41
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2020-08-20 |
| Est. Completion | 2024-01-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04218071
The ClinicalTrials.gov registry entry for NCT04218071 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Actuate Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ruxolitinib is the first listed.
NCT04218071 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04218071 about?
NCT04218071 is a clinical study titled "Actuate 1901: 9-ING-41 in Myelofibrosis". 9-ING-41 has anti-cancer clinical activity while not causing myelosuppression, and has both pre-clinical anti-fibrotic activity and activity against myelofibrosis. This Phase 2 study will study its efficacy in patients with advanced myelofibrosis.
What is the current status of trial NCT04218071?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2020-08-20. Estimated completion is 2024-01-18.
What interventions are being tested in trial NCT04218071?
The interventions under investigation include: Ruxolitinib (DRUG), 9-ING-41 (DRUG).
Who is sponsoring clinical trial NCT04218071?
This trial is sponsored by Actuate Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.